Suppr超能文献

前驱期亨廷顿病的连线测验:疾病进展对测验表现的影响。

The Trail Making Test in prodromal Huntington disease: contributions of disease progression to test performance.

机构信息

Department of Psychiatry, The University of Iowa, Iowa City, IA, USA.

出版信息

J Clin Exp Neuropsychol. 2011 Jun;33(5):567-79. doi: 10.1080/13803395.2010.541228. Epub 2011 Feb 7.

Abstract

We examined the Trail Making Test (TMT) in a sample of 767 participants with prodromal Huntington disease (prodromal HD) and 217 healthy comparisons to determine the contributions of motor, psychiatric, and cognitive changes to TMT scores. Eight traditional and derived TMT scores were also evaluated for their ability to differentiate prodromal participants closer to estimated age of diagnosis from those farther away and prodromal individuals from healthy comparisons. Results indicate that motor signs only mildly affected Part A, and psychiatric symptoms did not affect either part. Tests of perceptual processing, visual scanning, and attention were primarily associated with Part A, and executive functioning (response inhibition, set-shifting), processing speed, and working memory were associated with Part B. Additionally, TMT scores differentiated between healthy comparisons and prodromal HD individuals as far as 9-15 years before estimated diagnosis. In participants manifesting prodromal motor signs and psychiatric symptoms, the TMT primarily measures cognition and is able to discriminate between groups based on health status and estimated time to diagnosis.

摘要

我们在一组 767 名有前驱亨廷顿病(前驱 HD)的参与者和 217 名健康对照者中检查了 Trail Making Test(TMT),以确定运动、精神和认知变化对 TMT 评分的贡献。还评估了 8 种传统和衍生的 TMT 评分,以确定它们区分更接近估计诊断年龄的前驱参与者与更远的参与者以及前驱个体与健康对照者的能力。结果表明,运动迹象仅轻度影响 A 部分,而精神症状对两部分均无影响。感知处理、视觉扫描和注意力测试主要与 A 部分相关,而执行功能(反应抑制、思维转换)、处理速度和工作记忆与 B 部分相关。此外,TMT 评分能够在估计诊断前 9-15 年内区分健康对照者和前驱 HD 个体。在前驱运动症状和精神症状的参与者中,TMT 主要测量认知,并且能够根据健康状况和估计的诊断时间来区分组。

相似文献

1
The Trail Making Test in prodromal Huntington disease: contributions of disease progression to test performance.
J Clin Exp Neuropsychol. 2011 Jun;33(5):567-79. doi: 10.1080/13803395.2010.541228. Epub 2011 Feb 7.
2
Neurocognitive signs in prodromal Huntington disease.
Neuropsychology. 2011 Jan;25(1):1-14. doi: 10.1037/a0020937.
3
Everyday cognition in prodromal Huntington disease.
Neuropsychology. 2015 Mar;29(2):255-67. doi: 10.1037/neu0000102. Epub 2014 Jul 7.
4
Intra-individual Variability in Prodromal Huntington Disease and Its Relationship to Genetic Burden.
J Int Neuropsychol Soc. 2015 Jan;21(1):8-21. doi: 10.1017/S1355617714001076.
5
Depressive symptom severity is related to poorer cognitive performance in prodromal Huntington disease.
Neuropsychology. 2012 Sep;26(5):664-9. doi: 10.1037/a0029218. Epub 2012 Jul 30.
6
Cognitive and behavioral changes in Huntington disease before diagnosis.
Handb Clin Neurol. 2017;144:69-91. doi: 10.1016/B978-0-12-801893-4.00006-7.
7
Trail making test B and brain perfusion imaging in mild cognitive impairment and mild Alzheimer's disease.
Psychiatry Res. 2013 Sep 30;213(3):249-55. doi: 10.1016/j.pscychresns.2013.03.006. Epub 2013 Jul 5.
8
Cognitive domains that predict time to diagnosis in prodromal Huntington disease.
J Neurol Neurosurg Psychiatry. 2012 Jun;83(6):612-9. doi: 10.1136/jnnp-2011-301732. Epub 2012 Mar 26.

引用本文的文献

5
Safety, pharmacokinetics and pharmacodynamics of SBT-020 in patients with early stage Huntington's disease, a 2-part study.
Br J Clin Pharmacol. 2021 May;87(5):2290-2302. doi: 10.1111/bcp.14656. Epub 2020 Dec 29.
6
Time will tell: Decision making in premanifest and manifest Huntington's disease.
Brain Behav. 2020 Nov;10(11):e01843. doi: 10.1002/brb3.1843. Epub 2020 Sep 26.
7
Functional magnetic resonance imaging of the trail-making test in older adults.
PLoS One. 2020 May 12;15(5):e0232469. doi: 10.1371/journal.pone.0232469. eCollection 2020.
8
Movement Disorder Society Task Force Viewpoint: Huntington's Disease Diagnostic Categories.
Mov Disord Clin Pract. 2019 Aug 23;6(7):541-546. doi: 10.1002/mdc3.12808. eCollection 2019 Sep.
9
Visual Object Perception in Premanifest and Early Manifest Huntington's Disease.
Arch Clin Neuropsychol. 2019 Nov 27;34(8):1320-1328. doi: 10.1093/arclin/acz002.

本文引用的文献

1
Cognitive functioning in major depression--a summary.
Front Hum Neurosci. 2009 Sep 25;3:26. doi: 10.3389/neuro.09.026.2009. eCollection 2009.
2
Motor abnormalities in premanifest persons with Huntington's disease: the PREDICT-HD study.
Mov Disord. 2009 Sep 15;24(12):1763-72. doi: 10.1002/mds.22601.
3
CAG-repeat length and the age of onset in Huntington disease (HD): a review and validation study of statistical approaches.
Am J Med Genet B Neuropsychiatr Genet. 2010 Mar 5;153B(2):397-408. doi: 10.1002/ajmg.b.30992.
4
The Trail Making Test and its neurobehavioral components.
J Clin Exp Neuropsychol. 2010 Feb;32(2):159-63. doi: 10.1080/13803390902881942. Epub 2009 May 20.
6
Cognitive inhibition and working memory in unipolar depression.
J Affect Disord. 2009 Jul;116(1-2):100-5. doi: 10.1016/j.jad.2008.10.028. Epub 2008 Nov 29.
7
Memantine in the preventive treatment of refractory migraine.
Headache. 2008 Oct;48(9):1337-42. doi: 10.1111/j.1526-4610.2008.01083.x.
8
Phonemic fluency deficits in asymptomatic gene carriers for Huntington's disease.
Neuropsychology. 2008 Sep;22(5):596-605. doi: 10.1037/0894-4105.22.5.596.
9
Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity.
Brain. 2008 Apr;131(Pt 4):1057-68. doi: 10.1093/brain/awn025. Epub 2008 Mar 12.
10
Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL.
Lancet Neurol. 2008 Apr;7(4):310-8. doi: 10.1016/S1474-4422(08)70046-2. Epub 2008 Feb 28.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验